Earnings ·
Protalix BioTherapeutics reported second quarter 2026 financial results and a business update
PLXProtalix BioTherapeutics, Inc.
Protalix BioTherapeutics reported second quarter 2026 financial results and a business update. Revenues from selling goods increased to $19.8 million in Q2 2026, up from $15.4 million in the prior year period, driven by Elfabrio sales. Total revenue for the first half of 2026 reached $53.6 million, including a $25.0 million milestone payment from Chiesi, compared to $25.8 million in the same period last year. The company achieved net income of $22.1 million for the six months ended June 30, 2026, or $0.27 per share diluted. Cash and equivalents stood at $40.7 million as of June 30, 2026. Protalix reaffirmed its full-year 2026 total revenue guidance of $78.0 million to $83.0 million. The company operates in the biopharmaceutical industry, focusing on the discovery and commercialization of enzyme replacement therapies for rare diseases.